Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled Alpha-1 HC in Cystic Fibrosis
NCT01684410Phase 2Completed
- Sponsor
- Grifols
- Start
- Aug 2012
- Primary completion
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alpha-1-proteinase inhibitor in cystic fibrosis (CF) (3 arms), sponsored by Grifols. Primary endpoint: Adverse Events at 3 weeks. Started Aug 2012; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01684410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684410.